Allspring Global Investments Holdings LLC Reduces Stock Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Allspring Global Investments Holdings LLC decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 14.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,332 shares of the medical equipment provider's stock after selling 15,782 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.21% of BioLife Solutions worth $2,475,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BLFS. Stifel Financial Corp lifted its position in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock valued at $325,000 after buying an additional 670 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new position in BioLife Solutions during the third quarter valued at $28,000. Curi RMB Capital LLC lifted its position in BioLife Solutions by 0.5% during the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider's stock valued at $10,565,000 after buying an additional 2,283 shares during the period. Quest Partners LLC purchased a new position in BioLife Solutions during the third quarter valued at $57,000. Finally, Cerity Partners LLC lifted its position in BioLife Solutions by 6.6% during the third quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider's stock valued at $1,125,000 after buying an additional 2,776 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. KeyCorp lifted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. Finally, Benchmark reaffirmed a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.43.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now directly owns 276,315 shares in the company, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares of the company's stock, valued at $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,678 shares of company stock worth $317,990. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $26.67 on Friday. BioLife Solutions, Inc. has a one year low of $14.50 and a one year high of $29.55. The stock has a 50-day moving average of $26.93 and a 200 day moving average of $25.47. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -25.16 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.